Navigation Links
Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushing's disease patients in Phase III study
Date:3/7/2012

e of approximately 50% by month two, and remained stable in both groups through the end of the study. On average, as UFC levels were reduced, clinical manifestations of Cushing's disease improved including reduction of blood pressure, total cholesterol, weight and body mass index(1).

The most frequently reported adverse events (AE) (>10%) by investigators for pasireotide were diarrhea, nausea, hyperglycemia, cholelithiasis, abdominal pain, diabetes mellitus, injection site reactions, fatigue and increased glycosylated hemoglobin (HbA1c), with most events being Grade 1-2. The tolerability profile of pasireotide was similar to that of other somatostatin analogs with the exception of the greater degree of hyperglycemia.

The trial, which represents the largest randomized study to evaluate a medical therapy in patients with Cushing's disease, is the basis for regulatory submissions for pasireotide under way worldwide for the treatment of this condition. If approved, the brand name for pasireotide will be Signifor.

"These study results demonstrate that pasireotide has the potential to be an important therapeutic option for patients living with Cushing's disease and reinforces Novartis' commitment to develop therapies to help address unmet medical needs," said Herve Hoppenot, President, Novartis Oncology. "We look forward to working with regulatory authorities worldwide to help bring this novel treatment option to market."

About the Study

PASPORT-CUSHINGS (PASireotide clinical trial PORTfolio - CUSHING'S disease) is a prospective randomized, double-blind, Phase III study conducted at 68 sites in 18 countries. The study evaluated the efficacy and safety of pasireotide in 162 adult patients with persistent or recurrent Cushing's disease and UFC levels greater than 1.5 times the upper limit of normal (ULN), as well as in patients with newly diagnosed Cushing's disease who are not candidates for surgery(1).


'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... /PRNewswire-iReach/ -- Phoenix Houses of California ... is hosting its tenth annual "Triumph For Teens" Awards ... 2013.  More than 300 people are expected to attend ... treatment centers, family therapy, and prevention programs of Phoenix ... positive influences on the health and welfare of our community ...
(Date:5/24/2013)... Pa. , May 24, 2013  Auxilium Pharmaceuticals, ... executive management will participate in the Deutsche Bank Health ... Westin Boston Waterfront Hotel.  Mr. Adrian Adams ... to present an overview of the Company and its ... 29, 2013.   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) ...
(Date:5/23/2013)... May 24, 2013 3SBio Inc. (NASDAQ: ... a leading China -based biotechnology ... biopharmaceutical products, announced today that, at an extraordinary ... shareholders voted in favor of the proposal to ... plan of merger dated February 8, 2013, among ...
Breaking Medicine Technology:Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 2Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 43SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
(Date:5/25/2013)... Dr. Leslie Gerstman announced today that ... skin on the neck, on the brow and under the ... , Ultherapy is a non-surgical procedure for the face and ... lift the skin over time. The use of FDA-cleared ultrasound ... then treat the deepest support layers of the skin – ...
(Date:5/25/2013)... A disorder of the nerves, Diabetic ... According to neuropathy expert doctor Helen C Lin, on ... the disorder affects almost 50% of all Diabetic patients, ... The high blood sugar levels in the body are ... it usually tend to have abnormally high blood sugar ...
(Date:5/25/2013)... The report “Global Food Encapsulation Market ... Ingredients, Shell Materials, Packaging, & Geography: Trends & ... market with analysis and forecasting of the global ... driving and restraining factors for the global food ... challenges. The market is segmented and revenue are ...
(Date:5/25/2013)... Sun City Center, FL (PRWEB) May 25, 2013 ... years, is one of many of the NALA’s businesses throughout ... Owner, Craig Amshel chose to participate in the nationwide event ... served as a Lieutenant Colonel in the Army. He said, ... work in the community I serve, but I live here ...
(Date:5/25/2013)... 2013 By working diligently for months ... integration of the 2012 Lamborghini Aventador into their well-built ... entrant in the list of vehicles lined by SizeItUp ... all set to thrill automobile lovers in the year ... spectacular looks, the 2012 Lamborghini Aventador comes with extraordinarily ...
Breaking Medicine News(10 mins):Health News:Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ 2Health News:Diabetic Neuropathy treatment hits new grounds- Neuracel launches the complete natural treatment 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 3Health News:Dr. Craig Amshel of Absolute Surgical Specialists Offering Bowel Prep During the Shop Local for a Cause Event 2Health News:Rim Fitments Provider SizeItUp Launches The Database Integration For The 2012 Lamborghini Aventador 2
... ON., March 8, 2011Homeless patients cost about $2,500 more ... a new study by researchers at St. Michael,s Hospital. ... the hospital with underlying health issues and stay longer ... send them after their initial medical crisis has been ...
... Center,s Barrow Neurological Institute has received a $10.1 million ... and one of the biggest ever given to any ... Marian H. Rochelle to St. Joseph,s Barrow Neurological Institute ... medical frontier for psychiatric and motor disorders by using ...
... By Jenifer Goodwin HealthDay Reporter , ... old age, Americans have poorer health than their British ... on nearly 40,000 residents of the United States and ... surveys of the respective countries. After all ...
... sheds light--both literally and figuratively--on the intricate brain ... Stanford University recently used light to activate mouse ... or decrease anxiety-related behaviors. Pinpointing the origin of ... disorders, the most common class of psychiatric disease. ...
... -- Use of new data should speed diagnosis -- ... panel has revised and simplified the "McDonald Criteria" commonly ... should speed the diagnosis without compromising accuracy. The International ... the National MS Society and the European Committee for ...
... -- What difference does it make if homo sapiens ... as it turns out. Losing a few snippets of DNA ... of other mammals. It may also be the reason that male ... including chimpanzees and mice. It appears that a genetic trait ...
Cached Medicine News:Health News:Study: Homeless patients cost $2,500 more than the average patient for each hospital stay 2Health News:Deep brain stimulation research expands at Barrow 2Health News:Deep brain stimulation research expands at Barrow 3Health News:Americans Have Worse Health Than English Peers, Study Finds 2Health News:Americans Have Worse Health Than English Peers, Study Finds 3Health News:Americans Have Worse Health Than English Peers, Study Finds 4Health News:Researchers selectively control anxiety pathways in the brain 2Health News:International panel revises 'McDonald Criteria' for diagnosing multiple sclerosis 2Health News:International panel revises 'McDonald Criteria' for diagnosing multiple sclerosis 3Health News:International panel revises 'McDonald Criteria' for diagnosing multiple sclerosis 4Health News:International panel revises 'McDonald Criteria' for diagnosing multiple sclerosis 5Health News:Lost DNA May Have Made Us More Human 2
Double-ended, one end sharp, other end blunt, 7 1/2", double-ended, 5 mm wide....
... The Surgifoam* absorbable gelatin sponge, ... porcine gelatin absorbable sponge intended for ... bleeding surface. The sponge is off-white ... and speed to hemostasis, highly favorable ...
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches....
The Novus 2000 argon laser combines power, size, and versatility. Ideal for the office, clinic and operating room environments, Novus 2000 is the world's most widely accepted ophthalmic laser....
Medicine Products: